Evusheld receives Health Canada approval for pre-exposure prophylaxis (prevention) of COVID-19 in immune-compromised individuals

AstraZeneca

14 April 2022 - Evusheld is the first long-acting antibody combination to receive Health Canada authorisation for the prevention of COVID-19.

AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination has received a Notice of Compliance from Health Canada for the pre-exposure prophylaxis of COVID-19 in adults and adolescents (≥12 years of age weighing at least 40 kg), who have not had a known recent exposure to an individual infected with SARS-CoV-2 and who are immune-compromised and unlikely to mount an adequate immune response to COVID‐19 vaccination or for whom COVID-19 vaccination is not recommended. 

Read AstraZeneca press release

Michael Wonder

Posted by:

Michael Wonder